Tissue-based multigene expression tests for pretreatment prostate cancer risk assessment: current status and future...

Area of Science:

• Oncology
• Genetics
• Molecular Diagnostics

Background:

• Prostate cancer exhibits a wide range of aggressiveness, necessitating tailored treatment strategies.
• Active surveillance is a viable nonintervention option for low-risk prostate cancer, but requires precise risk assessment.
• Standard clinicopathological parameters may not fully capture the nuances of prostate cancer risk.

Purpose of the Study:

• To review selected tissue-based molecular assays for prostate cancer risk stratification.
• To emphasize the role of these assays in pretreatment risk assessment.
• To evaluate their current or potential utility in active surveillance protocols.

Main Methods:

• Review of literature on tissue-based molecular assays for prostate cancer.
• Focus on genomic prostate score, cell cycle progression score, and genomic classifier.
• Analysis of their application in pretreatment risk assessment and active surveillance.

Main Results:

• Molecular tests complement traditional methods for improved prostate cancer risk stratification.
• Specific assays demonstrate potential in identifying patients suitable for active surveillance.
• These tests aid in refining treatment decisions by providing a more granular risk profile.

Conclusions:

• Molecular assays are valuable tools for enhancing risk assessment in prostate cancer.
• Their application in a pretreatment setting can guide the selection of active surveillance.
• Further integration of these tests may optimize management strategies for low-risk prostate cancer.